Valneva has just announced the top line results of its phase 3 trial, Cov-Compare, of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The press release was released this morning: https://valneva.com/press-release/valneva-reports-positive-phase-3-results-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/
Journalists dialled in to this Q&A press briefing to hear from some of the scientists leading the trial and ask them their questions.
Prof Adam Finn, Professor of Paediatrics at the University of Bristol, and Trial Chief Investigator
Dr Juan Carlos Jaramillo, Valneva’s Chief Medical Officer
This Briefing was accompanied by an SMC Roundup of Comments.